TY - JOUR
T1 - Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics
T2 - practical nuances and intricacies
AU - Iravani, Amir
AU - Violet, John
AU - Azad, Arun
AU - Hofman, Michael S.
N1 - Funding Information:
Acknowledgements MSH is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation, with research support from the Movember, Prostate Cancer Foundation of Australia (PCFA), Prostate Cancer Foundtion (PCF) and Department of Defence - Con-gresionally Directed Medical Research Program (CDRP). For our phase II trial, 177Lu (no carrier added) was supplied by the Australian National Nuclear Science and Technology Organisation (ANSTO) and PSMA-617 was supplied by Advanced Biochemical Compounds (ABX, Radeberg, Germany) and Endocyte, a Novartis company (USA).
Funding Information:
Conflict of interest AA reports personal fees from Janssen, grants, personal fees, and nonfinancial support from Astellas, personal fees from Novartis, grants and nonfinancial support from Merck Serono, personal fees from Tolmar, personal fees and nonfinancial support from Amgen, personal fees from Pfizer, personal fees from Bayer, personal fees from Telix Pharmaceuticals, personal fees from Bristol-Myers Squibb and personal fees from Sanofi. MSH reports personal fees and travel reimbursement for delivering educational talks at meetings supported by Ipsen, Sanofi Genzyme, and Jannsen, research support from Endocyte, a Novartis company. The remaining authors declare that they have no conflict of interest.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting opportunity for a highly personalized treatment strategy in the era of precision medicine. Prostate-specific membrane antigen (PSMA) theranostics has attracted increasing attention as a promising targeted treatment in metastatic prostate cancer (PC). 177Lu-DOTA-PSMA-617 (177Lu-PSMA-617) is a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioligand for radionuclide therapy (RNT) in PC. Since 2014 multiple retrospective studies and more recently a phase II prospective study demonstrated safety and impressive efficacy of 177Lu-PSMA RNT. The evidence generated by these trials led to two currently underway randomized trials in metastatic castrate-resistant PC: TheraP (NCT03392428) and VISION (NCT03511664). While we wait for these pivotal trials to read out, nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists are facing a steep learning curve to master the intricacies and nuances of this novel therapeutic strategy. This review article aims to share and discuss the evolving experience in practical aspects of PSMA theranostics.
AB - Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting opportunity for a highly personalized treatment strategy in the era of precision medicine. Prostate-specific membrane antigen (PSMA) theranostics has attracted increasing attention as a promising targeted treatment in metastatic prostate cancer (PC). 177Lu-DOTA-PSMA-617 (177Lu-PSMA-617) is a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioligand for radionuclide therapy (RNT) in PC. Since 2014 multiple retrospective studies and more recently a phase II prospective study demonstrated safety and impressive efficacy of 177Lu-PSMA RNT. The evidence generated by these trials led to two currently underway randomized trials in metastatic castrate-resistant PC: TheraP (NCT03392428) and VISION (NCT03511664). While we wait for these pivotal trials to read out, nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists are facing a steep learning curve to master the intricacies and nuances of this novel therapeutic strategy. This review article aims to share and discuss the evolving experience in practical aspects of PSMA theranostics.
UR - http://www.scopus.com/inward/record.url?scp=85074555137&partnerID=8YFLogxK
U2 - 10.1038/s41391-019-0174-x
DO - 10.1038/s41391-019-0174-x
M3 - Review article
C2 - 31595044
AN - SCOPUS:85074555137
SN - 1365-7852
VL - 23
SP - 38
EP - 52
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 1
ER -